drugset
drugset / Trial / NCT06181006

A Study to Evaluate Pirtobrutinib (LOXO-305) in Healthy Adult Participants

NCT06181006 ↗

Phase 1 Completed 24 enrolled Eli Lilly and Company Loxo Oncology, Inc. · collab
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The main purpose of this study is to assess the safety and tolerability of pirtobrutinib and to look at the amount of the study drug, pirtobrutinib, that gets into the blood stream and how long it takes the body to get rid of it when given in healthy adult participants. For each participant, the total duration of the study will be 46 days, including screening.

Timeline

Start
2020-08-14
Primary completion
2020-12-01
Completion
2020-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Pirtobrutinib Other / unclassified 300 mg Oral
Subject Pirtobrutinib Other / unclassified 600 mg Oral
Subject Pirtobrutinib Other / unclassified 800 mg Oral
Subject Pirtobrutinib Other / unclassified 900 mg Oral

Indications

No indication recorded.